{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:41:32Z","timestamp":1793677292196,"version":"4.5.1"},"reference-count":26,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,14]]},"DOI":"10.1182\/bloodadvances.2021005020","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T03:59:21Z","timestamp":1634529561000},"page":"5344-5348","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":50,"title":["Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma"],"prefix":"10.1182","volume":"5","author":[{"given":"Vanessa E.","family":"Kennedy","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Wong","sequence":"additional","affiliation":[{"name":"2School of Medicine, Touro University California, Vallejo, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2313-3562","authenticated-orcid":false,"given":"Chiung-Yu","family":"Huang","sequence":"additional","affiliation":[{"name":"3Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wolf","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy W.","family":"Wong","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"issue":"13","key":"2025050215310548400_bib1","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood."},{"issue":"22","key":"2025050215310548400_bib2","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol."},{"issue":"6","key":"2025050215310548400_bib3","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest."},{"issue":"18","key":"2025050215310548400_bib4","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med."},{"issue":"19","key":"2025050215310548400_bib5","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"issue":"1","key":"2025050215310548400_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol."},{"issue":"1","key":"2025050215310548400_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/MOP.0b013e32834ec9c1","article-title":"Hemophagocytic lymphohistiocytosis: updates and evolving concepts","volume":"24","author":"Risma","year":"2012","journal-title":"Curr Opin Pediatr."},{"issue":"7","key":"2025050215310548400_bib8","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/10428194.2021.1881507","article-title":"Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature","volume":"62","author":"Major","year":"2021","journal-title":"Leuk Lymphoma."},{"issue":"303","key":"2025050215310548400_bib9","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med."},{"issue":"26","key":"2025050215310548400_bib10","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"17","key":"2025050215310548400_bib11","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol."},{"issue":"22","key":"2025050215310548400_bib12","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1182\/blood.V128.22.3358.3358","article-title":"Tocilizumab-refractory cytokine release syndrome (CRS) triggered by chimeric antigen receptor (CAR)-transduced T cells may have distinct cytokine profiles compared to typical CRS","volume":"128","author":"Ishii","year":"2016","journal-title":"Blood."},{"issue":"1","key":"2025050215310548400_bib13","first-page":"29","article-title":"Diagnostic guidelines for hemophagocytic lymphohistiocytosis","volume":"18","author":"Henter","year":"1991","journal-title":"Semin Oncol."},{"issue":"2","key":"2025050215310548400_bib14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"2025050215310548400_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"issue":"4","key":"2025050215310548400_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"15","key":"2025050215310548400_bib17","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"issue":"8","key":"2025050215310548400_bib18","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"24","key":"2025050215310548400_bib19","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood."},{"issue":"8","key":"2025050215310548400_bib20","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-018-3368-8","article-title":"The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review","volume":"97","author":"Jin","year":"2018","journal-title":"Ann Hematol."},{"issue":"224","key":"2025050215310548400_bib21","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med."},{"issue":"9967","key":"2025050215310548400_bib22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet."},{"key":"2025050215310548400_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/JBM.S46255","article-title":"Hemophagocytic lymphohistiocytosis: review of etiologies and management","volume":"5","author":"George","year":"2014","journal-title":"J Blood Med."},{"issue":"6","key":"2025050215310548400_bib24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med."},{"issue":"1","key":"2025050215310548400_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol."},{"issue":"6","key":"2025050215310548400_bib26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med."}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2023010575","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5344\/2372808\/blooda_adv-2021-005020-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5344\/2372808\/blooda_adv-2021-005020-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T19:31:17Z","timestamp":1746214277000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/23\/5344\/477277\/Macrophage-activation-syndrome-like-MAS-L"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":26,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,12,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005020","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2023010575","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]}}}